JP2022519675A5 - - Google Patents
Info
- Publication number
- JP2022519675A5 JP2022519675A5 JP2021545958A JP2021545958A JP2022519675A5 JP 2022519675 A5 JP2022519675 A5 JP 2022519675A5 JP 2021545958 A JP2021545958 A JP 2021545958A JP 2021545958 A JP2021545958 A JP 2021545958A JP 2022519675 A5 JP2022519675 A5 JP 2022519675A5
- Authority
- JP
- Japan
- Prior art keywords
- grade
- use according
- topical composition
- composition
- severity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962804235P | 2019-02-12 | 2019-02-12 | |
| US62/804,235 | 2019-02-12 | ||
| PCT/IB2020/051073 WO2020165755A1 (en) | 2019-02-12 | 2020-02-11 | Use of topical braf inhibitor compositions for treatment of radiation dermatitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022519675A JP2022519675A (ja) | 2022-03-24 |
| JP2022519675A5 true JP2022519675A5 (cg-RX-API-DMAC7.html) | 2023-01-05 |
Family
ID=72044789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021545958A Pending JP2022519675A (ja) | 2019-02-12 | 2020-02-11 | 放射線皮膚炎の治療のための局所用ｂｒａｆ阻害剤組成物の使用 |
Country Status (17)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022136912A1 (en) * | 2020-12-24 | 2022-06-30 | Lutris Pharma Ltd. | Topical braf inhibitor compositions for treatment of egfr downstream effectors - induced reactions |
| WO2023275620A2 (en) * | 2021-07-02 | 2023-01-05 | Lutris Pharma Ltd. | Use of isoquinoline-1,5-diamines for wound healing |
| WO2023051685A1 (zh) * | 2021-09-30 | 2023-04-06 | 北京大学 | 一种对红系前体细胞或成红细胞进行扩增的方法及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5753612A (en) | 1992-10-27 | 1998-05-19 | Yissum Research Development Co. Of The Hebrew University Of Jerusalem | Pharmaceutical composition and method for inhibiting hair growth by administration of activin or activin agonists |
| US7989461B2 (en) | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
| US8557830B2 (en) | 2007-06-07 | 2013-10-15 | Amgen Inc. | RAF kinase modulators and methods of use |
| AU2009226136B2 (en) * | 2008-03-17 | 2013-08-15 | Ambit Biosciences Corporation | Quinazoline derivatives as RAF kinase modulators and methods of use thereof |
| US9290507B2 (en) * | 2010-03-26 | 2016-03-22 | Boehringer Ingelheim International Gmbh | B-RAF kinase inhibitors |
| TWI611053B (zh) | 2012-02-27 | 2018-01-11 | 曾宇鳳 | 為先導藥物最適化之以結構為基礎的片段遷越及合成可行性之改良 |
| KR20140011780A (ko) | 2012-07-19 | 2014-01-29 | 한미약품 주식회사 | 단백질 키나아제 저해활성을 갖는 이소퀴놀린-5-카복스아미드 유도체 |
| CN106535900A (zh) * | 2014-05-06 | 2017-03-22 | 加利福尼亚大学董事会 | 使用braf抑制剂的伤口愈合 |
| CN109069511A (zh) | 2016-03-10 | 2018-12-21 | 鲁特里斯制药有限公司 | Braf抑制剂用于治疗皮肤反应的用途 |
| SI3661515T1 (sl) * | 2017-07-29 | 2022-06-30 | Lutris Pharma Ltd. | Novi BRaf inhibitorji in njihova uporaba za zadravljenje kožnih reakcij |
| US11458139B2 (en) * | 2017-08-08 | 2022-10-04 | Memorial Sloan Kettering Cancer Center | Use of BRAF inhibitors for treating cutaneous reactions caused by treatment with a MEK inhibitor |
-
2020
- 2020-02-11 MX MX2021009535A patent/MX2021009535A/es unknown
- 2020-02-11 PL PL20756229.9T patent/PL3923911T3/pl unknown
- 2020-02-11 BR BR112021015137-0A patent/BR112021015137A2/pt unknown
- 2020-02-11 HU HUE20756229A patent/HUE063091T2/hu unknown
- 2020-02-11 HR HRP20231241TT patent/HRP20231241T1/hr unknown
- 2020-02-11 CA CA3127175A patent/CA3127175C/en active Active
- 2020-02-11 KR KR1020217029012A patent/KR102534457B1/ko active Active
- 2020-02-11 EP EP20756229.9A patent/EP3923911B1/en active Active
- 2020-02-11 JP JP2021545958A patent/JP2022519675A/ja active Pending
- 2020-02-11 AU AU2020220895A patent/AU2020220895B9/en active Active
- 2020-02-11 ES ES20756229T patent/ES2952251T3/es active Active
- 2020-02-11 CN CN202080012207.4A patent/CN113382717A/zh active Pending
- 2020-02-11 WO PCT/IB2020/051073 patent/WO2020165755A1/en not_active Ceased
- 2020-02-11 RS RS20230855A patent/RS64618B1/sr unknown
- 2020-02-11 IL IL285560A patent/IL285560B2/en unknown
-
2021
- 2021-07-23 US US17/384,221 patent/US11439648B2/en active Active
- 2021-09-07 ZA ZA2021/06581A patent/ZA202106581B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2745415C (en) | Methods for preventing or reducing carcinogenesis or oxidative stress | |
| JP2019189650A5 (cg-RX-API-DMAC7.html) | ||
| RU2644635C2 (ru) | Системы, способы и составы для лечения рака | |
| JP5911929B2 (ja) | 特定の癌の治療のためのｒｄｅａ１１９／ｂａｙ８６９７６６を含む組み合わせ医薬 | |
| JP2022188083A5 (cg-RX-API-DMAC7.html) | ||
| ES2911110T3 (es) | Combinaciones de tofacitinib y crisaborol para uso en el tratamiento de enfermedades inflamatorias de la piel | |
| JP2017528505A5 (cg-RX-API-DMAC7.html) | ||
| JP2009534306A5 (cg-RX-API-DMAC7.html) | ||
| CN101972225A (zh) | 一种含吡非尼酮的凝胶组合物 | |
| RU2013100383A (ru) | Композиции полиэтиленгликоля для контроля рецидивов лабиального герпеса, генитального герпеса и опоясывающего герпеса | |
| HRP20231241T1 (hr) | Upotreba sastava braf inhibitora za lokalnu primjenu za liječenje radijacijskog dermatitisa | |
| JP2012525358A5 (cg-RX-API-DMAC7.html) | ||
| AU780844B2 (en) | Method for protecting normal cells from cytotoxicity of chemotherapeutic agents | |
| JP2015081244A (ja) | ニキビ治療用医薬組成物 | |
| JP2010504969A (ja) | Ｓａｈａのアミン塩基塩及びその多形 | |
| EP3592351A1 (en) | 1-piperidinepropionic acid for treating a fibrosing disease | |
| RU2021126784A (ru) | Применение композиций на основе ингибитора braf для наружнего применения для лечения лучевого дерматита | |
| CA2489705A1 (en) | Use of amide derivative of ge 2270 factor a3 for the treatment of acne | |
| JP2017530132A5 (cg-RX-API-DMAC7.html) | ||
| JP2023502251A (ja) | ファルネソイドｘ受容体（ｆｘｒ）を介した転写応答を誘導または促進する方法 | |
| RU2812708C2 (ru) | Применение композиций на основе ингибитора braf для наружного применения для лечения лучевого дерматита | |
| WO2017096025A1 (en) | Norpregnane derivatives for the risk reduction of breast cancer | |
| Wang et al. | 657 TGF-β2 upregulates OPN3 in human epidermal melanocytes independent of TGF-β2R in vitro | |
| Gibson et al. | 660 Dual HDAC and LSD1 inhibition as a novel strategy to overcome BRAF inhibitor resistance | |
| JPS60146823A (ja) | 消炎鎮痛性外用医薬組成物 |